Healthia (ASX:HLA) - Managing Director & Group CEO, Wesley Coote
Managing Director & Group CEO, Wesley Coote
Source: Healthia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthia (HLA) raises $44.5 million through a placement and the institutional component of its fully underwritten entitlement offer
  • The company recently flagged a $60 million capital raise to partially fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics
  • This purchase is set to position HLA as a leading provider of physiotherapy services in Australia and expand its presence to WA and New Zealand
  • Healthia will raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6
  • Company shares are down 1.88 per cent to trade at $2.09

Healthia (HLA) has completed a placement and the institutional component of its fully underwritten one-for-4.3 pro rata non-renounceable entitlement offer.

As announced at the start of the week, Healthia is launching a $60 million capital raise to fund the acquisition of the Back in Motion Health Group and its 64 physiotherapy clinics throughout Australia and New Zealand for a cash and share consideration of $88.4 million.

Healthia considers the buy to be a strategic way of positioning it as a leading provider of physiotherapy services in Australia and expanding its presence to the WA and New Zealand markets.

The placement and institutional entitlement offer raised a combined total of about $44.5 million at a price of $1.80 per share.

The offer price represents an 18.2 per cent discount to the last closing price of $2.20 on September 17 and a 9.3 per cent discount to the five-day volume-weighted average price of $1.98.

Broken down, Healthia agreed to issue roughly 12.4 million shares to raise $22.3 million without the need for shareholder approval. The institutional offer raised $22.2 million through the issue of about 12.34 million shares and saw a significant take-up of entitlements by institutional shareholders.

The company expects to raise the remaining $15.5 million through the retail component of its entitlement offer which will be open from September 27 until October 6.

Company shares were down 1.88 per cent to trade at $2.09 at 1:50 pm AEST.

HLA by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars